Recent studies have focused on the overlap of GLP|GIP|GCGR agonist therapies and dopaminergic neurotransmission. While GLP agonists are commonly employed for treating type 2 T2DM, their potential consequences on reward https://semaglutide423277.techionblog.com/42044349/novel-gip-activators-and-dopamine-adjustment-a-comparative-assessment